Z-1651-2022 Class II Ongoing

Recalled by Qiagen Sciences LLC — Germantown, MD

FDA device recall Z-1651-2022 was initiated by Qiagen Sciences LLC on Jul 20, 2022 and is designated Class II. Reason for recall: Increased occurrence rate of false positive results, lead to a false positive sample result that could subsequently be incorrectly reported from the laboratory. A false positive result could lead to… The recall status is ongoing. Affected quantity: 29 kits.

Recall details

Product Type
Devices
Report Date
Sep 7, 2022
Initiation Date
Jul 20, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
29 kits

Product description

therascreen FGFR RGQ RT-PCR Kit (CE IVD, not sold in the US) REF 874711

Reason for recall

Increased occurrence rate of false positive results, lead to a false positive sample result that could subsequently be incorrectly reported from the laboratory. A false positive result could lead to the risk of the patient being exposed to an inappropriate or suboptimal anti-cancer treatment and/or unnecessarily experiencing side effects

Distribution pattern

IN, NC, MN, TX Foreign: Belgium, China, Germany, Jordan, Italy, Netherlands, Malaysia, Spain, Thailand

Code information

Lot number: 172017804 Exp Date: 10.11.2022 169046610 Exp. Date: 12.06.2022

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-1651-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-1651-2022. Report a data issue: hello@regdatalab.com.